Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden

Overview

This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for supportive care and mortality. All patients treated with ASCT in Sweden from 1st January 2020 until 31st December 2020 are eligible for this study. Patients who also has tested positive for SARS-CoV-2 from start of conditioning or later will be identified through the national registry of the Public Health Agency of Sweden and a systematic analysis of their medical records will be performed.

Full Title of Study: “Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden – a Retrospective Cohort Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: August 30, 2021

Detailed Description

Research question How does infection with SARS-CoV-2 affect patients with hematological malignancies who are treated with autologous hematopoietic stem cell transplantation? Study population All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 are eligible for this study. There will be a minimum follow-up time of one month for all patients. Data collection and storage Patients will be identified using local ASCT registers at the seven university hospitals, as there is no national register for ASCT-patients in Sweden. These seven university hospitals are the only sights to perform ASCT in Sweden. The Public Health Agency of Sweden (Folkhälsomyndigheten – FHM) has the national responsibility to surveil and control communicable disease. The FHM uses several different surveillance systems to monitor the spread of COVID-19. Since COVID-19 is subject to mandatory reporting under the Communicable Diseases Act, physicians and laboratories continuously supply data to be analyzed daily by the FHM. The coverage of this database is estimated to be very high, close to 100%. For this study the investigators will link the patients identified through the ASCT-centers with the register of SARS-Cov-2 positive patients (SmiNet) held by the FHM. Patients who has tested positive for SARS-CoV-2 on the day of start of conditioning or at any given time thereafter will be included in the study. Inclusion of positive SARS-CoV-2 tests will start from 1st January 2020 until 31st March 2021 to allow for 3 months of follow-up after transplantation. For every ASCT-patient that has tested positive for COVID-19 after ASCT a systematic analysis of their medical records will be performed to describe the circumstances, impact and outcome of the COVID-19. All data collected will be stored in a deidentified data set on a secure server held by Dalarna Country Council where name and social security number have been erased and given a coded study number. Each patient will only be identified using a separately stored code key. All storage, correspondence and analysis with the code key and pseudonymized data set will adhere to current European General Data Protection Regulation (GDPR) guidelines. The code key will be destroyed as soon as data collection is completed, data quality is secured and the final report is published. The data set will be stored for 10 years and then be destroyed.

Interventions

  • Other: Autologous stem cell transplantation
    • The study will describe the implications of COVID-19 infection following autologous stem cell transplantation

Arms, Groups and Cohorts

  • COVID19 positives after autologous stem cell transplantation
    • All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 who has tested positive for SARS-CoV-2 from start of conditioning until the end of the study period 31st March 2021.

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: 30 days
    • Overall survival after infection with COVID-19
  • Overall survival
    • Time Frame: 90 days
    • Overall survival after infection with COVID-19
  • COVID-19 related mortality
    • Time Frame: within 6 months after infection
    • As classified by the WHO; a death resulting from a clinically compatible illness in a confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID disease (e.g., trauma). There should be no period of complete recovery between the illness and death

Secondary Measures

  • Time of COVID-19 infection
    • Time Frame: Up to 15 months
    • Time of SARS-CoV-2 infection in relation to autologous stem cell transplantation
  • Hospitalization
    • Time Frame: Up to 15 months
    • Duration of hospitalization
  • Oxygen treatment
    • Time Frame: Up to 15 months
    • Duration of oxygen treatment
  • High-flow oxygen therapy
    • Time Frame: Up to 15 months
    • Duration of high-flow oxygen therapy
  • Non-invasive ventilation
    • Time Frame: Up to 15 months
    • Duration of non-invasive ventilation (NIV)
  • Intensive care
    • Time Frame: Up to 15 months
    • Duration of care in intensive care unit
  • Invasive mechanical ventilation
    • Time Frame: Up to 15 months
    • Duration of Invasive mechanical ventilation
  • ECMO
    • Time Frame: Up to 15 months
    • Duration of extracorporeal membrane oxygenation (ECMO)
  • Occurence of ARDS
    • Time Frame: Up to 15 months
    • Diagnosis of Acute respiratory distress syndrome (ARDS)
  • Occurence of arterial thrombosis
    • Time Frame: Up to 15 months
    • Event of arterial thrombosis
  • Occurence of venous thrombosis
    • Time Frame: Up to 15 months
    • Event of venous thrombosis
  • Occurence of arrhythmias
    • Time Frame: Up to 15 months
    • Event of recorded arrhythmias
  • Occurence of acute cardiac injury
    • Time Frame: Up to 15 months
    • Event of acute cardiac injury
  • Occurence of secondary infection
    • Time Frame: Up to 15 months
    • Event of any secondary infection
  • Occurence of cytokine release syndrome
    • Time Frame: Up to 15 months
    • Event of cytokine release syndrome
  • Comorbidities
    • Time Frame: Prior to autologous stem cell transplantation
    • Description of comorbidities prior to autologous stem cell transplantation
  • Disease status
    • Time Frame: Prior to autologous stem cell transplantation
    • Description of disease status prior to autologous stem cell transplantation
  • Previous disease modifying treatment
    • Time Frame: Prior to autologous stem cell transplantation
    • Description of previous disease modifying treatment prior to autologous stem cell transplantation
  • Conditioning treatment
    • Time Frame: At autologous stem cell transplantation
    • Description of conditioning treatment prior to autologous stem cell transplantation
  • Time of infection
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Time of COVID-19 in relation to autologous stem cell transplantation
  • Neutropenia
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of neutropenia at diagnosis of COVID-19
  • Elevated CRP
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated C-reactive protein (CRP) at diagnosis of COVID-19
  • Elevated leukocyte count
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated leukocyte count at diagnosis of COVID-19
  • Lymphocytopenia
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of lymphocytopenia at diagnosis of COVID-19
  • Elevated liver enzymes
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated liver enzymes at diagnosis of COVID-19
  • Elevated lactate dehydrogenase
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated lactate dehydrogenase at diagnosis of COVID-19
  • Elevated ferritin
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated ferritin at diagnosis of COVID-19
  • Elevated d-dimer
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated d-dimer at diagnosis of COVID-19
  • Prolonged aPTT
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of prolonged activated partial thromboplastin time (aPTT) at diagnosis of COVID-19
  • Elevated troponin
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated troponin at diagnosis of COVID-19
  • Elevated creatinine
    • Time Frame: At autologous stem cell transplantation or up to 15 months
    • Event of elevated creatinine at diagnosis of COVID-19

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of hematological cancer (C81-C96 according to the International Classification of Diseases 10th revision (ICD-10). – Autologous hematopoietic stem cell transplantation performed 1 January 2020 until 31st December 2020 at a Swedish transplantation center. – Positive RT-PCR test for SARS-CoV-2 performed in Sweden Exclusion Criteria:

  • Age below 18 years and 0 months at the time of transplantation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Uppsala University
  • Collaborator
    • Karolinska University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Honar Cherif, MD, Ass prof, Principal Investigator, Department of Medical Sciences, Uppsala University
    • Thomas Silfverberg, MD, Study Chair, Center for Clinical Research Dalarna and Department of Medical Sciences-Uppsala University
    • Kristina Carlson, MD, Ass Prof, Study Chair, Department of Medical Sciences, Uppsala University

References

Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020 Feb 25;323(8):709-710. doi: 10.1001/jama.2020.1097. No abstract available.

Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 1996 Aug;18(2):265-71.

Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, Brinch L, Brune M, De La Camara R, Dekker A, Pauksen K, Russell N, Schwarer AP, Cordonnier C. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001 Sep;28(5):479-84. doi: 10.1038/sj.bmt.1703139.

Hutspardol S, Essa M, Richardson S, Schechter T, Ali M, Krueger J, Fujii H, Egeler RM, Gassas A. Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7. doi: 10.1016/j.bbmt.2015.06.015. Epub 2015 Jun 25.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:

Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 Jul;54(7):1058-1066. doi: 10.1038/s41409-018-0386-z. Epub 2018 Nov 1.

He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP. COVID-19 in persons with haematological cancers. Leukemia. 2020 Jun;34(6):1637-1645. doi: 10.1038/s41375-020-0836-7. Epub 2020 Apr 24.

Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Murray J, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Verhoeven B, Kroger N, Styczynski J; European Society for Blood and Marrow Transplantation. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020 Nov;55(11):2071-2076. doi: 10.1038/s41409-020-0919-0. Epub 2020 May 13. Erratum In: Bone Marrow Transplant. 2020 Jun 8;:

Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NWCJ, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H, Zweegman S, Moreau P, Einsele H, Boccadoro M, San Miguel J, Dimopoulos MA, Sonneveld P. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020 Aug;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z. Epub 2020 May 22.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020 Jun;10(6):783-791. doi: 10.1158/2159-8290.CD-20-0422. Epub 2020 Apr 28.

Pinana JL, Martino R, Garcia-Garcia I, Parody R, Morales MD, Benzo G, Gomez-Catalan I, Coll R, De La Fuente I, Luna A, Merchan B, Chinea A, de Miguel D, Serrano A, Perez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martinez D, Jurado M, Calbacho M, Vazquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldana R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernandez N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020.

Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertu L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.